Sermorelin Dosing for Adults
Based on FDA-approved labeling and clinical research, sermorelin for adults is administered subcutaneously at 30 mcg/kg once daily at bedtime, though this dosing was primarily established in pediatric populations and extrapolated to adults with growth hormone deficiency. 1
Initial Dosing Protocol
Subcutaneous administration: The standard starting dose is 30 mcg/kg bodyweight given once daily at bedtime 2. This timing capitalizes on the physiological nocturnal surge of growth hormone secretion.
For practical application in adults:
- Calculate dose based on actual body weight
- Administer via subcutaneous injection
- Timing: bedtime administration is critical for optimal efficacy
Titration and Dose Adjustment
The evidence does not support routine dose escalation beyond the initial 30 mcg/kg dose. Alternative dosing regimens have been studied, including:
- 100 mcg three times daily (thrice-daily dosing) of combined GHRP-6, GHRP-2, and sermorelin in hypogonadal men seeking body composition changes 3
- This higher-frequency regimen requires strict compliance to achieve therapeutic IGF-1 elevation
Critical caveat: The thrice-daily regimen showed efficacy only with strict adherence to the dosing schedule. Mean treatment duration in the research setting was 134 days 3.
Maximum Dose
The FDA labeling does not establish a specific maximum dose for sermorelin in adults. Pediatric data used up to 30 mcg/kg without dose escalation 2. The thrice-daily 100 mcg regimen (total 300 mcg/day) represents the upper range studied in adults 3.
Treatment Duration
Initial assessment period: 12 months is the standard duration for evaluating treatment response in growth hormone deficiency 2. Limited data suggest sustained effects through 36 months of continued treatment in pediatric populations.
For body composition goals: Treatment duration of approximately 4-5 months (mean 134 days) was studied in adults 3.
Monitoring Requirements
Baseline Assessment
- IGF-1 levels (serves as surrogate marker for growth hormone)
- Growth hormone stimulation testing if diagnosing GH deficiency
- Baseline body composition measurements if treating for body composition changes
During Treatment
- IGF-1 monitoring: Check serum IGF-1 levels periodically to assess response 3
- Baseline IGF-1 should be documented
- Post-treatment IGF-1 elevation confirms biological response
- In the research cohort, mean IGF-1 increased from 159.5 ng/mL to 239.0 ng/mL (p<0.0001)
Important Drug Interactions
Aromatase inhibitors and selective estrogen receptor modulators (SERMs) blunt the IGF-1 response to sermorelin 3. If concurrent use is necessary, expect smaller increases in IGF-1 levels and potentially reduced clinical efficacy.
Safety and Tolerability
Common adverse events:
- Transient facial flushing (most common)
- Pain at injection site
- Both are generally mild and well-tolerated 2
Sermorelin is well-tolerated with both single-dose and repeated daily subcutaneous administration. No serious adverse events were consistently reported in the available evidence.
Clinical Pitfalls
Compliance is critical: The thrice-daily regimen requires strict adherence—only 14 of 105 men in one study met strict compliance criteria 3
Concurrent estrogen modulation: Co-administration of aromatase inhibitors or tamoxifen significantly reduces IGF-1 response 3
Diagnostic vs. therapeutic use: Single IV doses (1 mcg/kg) are used for GH deficiency testing, while daily subcutaneous doses (30 mcg/kg) are used therapeutically 2
Response variability: Not all patients respond equally—slower growing children with delayed bone age showed better responses in pediatric studies, suggesting patient selection matters 2